Detalhe da pesquisa
1.
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Antimicrob Agents Chemother
; 61(8)2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28559269
2.
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Int J Tuberc Lung Dis
; 27(1): 34-40, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853128
3.
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Int J Tuberc Lung Dis
; 27(6): 451-457, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37231598
4.
Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
Antimicrob Agents Chemother
; 61(9)2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28839086
5.
Factors associated with screening failure and study withdrawal in multidrug-resistant TB.
Int J Tuberc Lung Dis
; 26(9): 820-825, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35996282
6.
Using digital chatbots to close gaps in healthcare access during the COVID-19 pandemic.
Public Health Action
; 12(4): 180-185, 2022 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36561900
7.
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.
Eur Respir J
; 38(3): 516-28, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21828024
8.
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Trials
; 22(1): 651, 2021 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34563240
9.
Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data.
Int J Tuberc Lung Dis
; 24(11): 1151-1155, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172522
10.
The fourth national anti-tuberculosis drug resistance survey in Peru.
Int J Tuberc Lung Dis
; 24(2): 207-213, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32127106
11.
Introducing new and repurposed TB drugs: the endTB experience.
Int J Tuberc Lung Dis
; 24(10): 1081-1086, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33126943
12.
Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study.
Public Health Action
; 9(1): 32-41, 2019 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30963040
13.
Screening with GenoType® MTBDRplus shortens the time to MDR-TB treatment initiation but does not change outcomes.
Int J Tuberc Lung Dis
; 27(12): 949-951, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38042965
14.
Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru.
Int J Tuberc Lung Dis
; 22(1): 86-92, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29297431
15.
Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.
Int J Tuberc Lung Dis
; 21(1): 6-11, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28157458
16.
Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.
Int J Tuberc Lung Dis
; 21(8): 894-901, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28786798
17.
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.
Int J Tuberc Lung Dis
; 10(3): 290-6, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16562709
18.
(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis
; 20(12): 18-23, 2016 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28240568
19.
TB research requires strong protections, innovation, and increased funding in response to COVID-19.
Trials
; 22(1): 371, 2021 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051826
20.
Sputum culture conversion definitions and analytic practices for multidrug-resistant TB.
Int J Tuberc Lung Dis
; 25(7): 596-598, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34183109